As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...

Explore the benefits and side effects of popular weight loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. Learn how ...

Journal Editorial Report: The year's best from Kim Strassel, Kyle Peterson, Mary O'Grady, Dan Henninger and Paul Gigot. Photo: VATICAN MEDIA/Zuma Press A patient once stopped midsentence in my therapy ...

The Easy A actress recently revealed that she’s lost nearly 30 lbs. using Ozempic, sharing how it’s pushing her to continue her health goals. “I usually don’t like paparazzi pictures bc I was 180lbs ...

Ozempic started the weight-loss drug frenzy, and it continues to be a famous name in the fight against obesity, even though it's not approved for that purpose. The blockbuster medication is meant to ...

Karlawish is a professor of medicine, medical ethics, health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine, co-director of the Penn Memory Center, and executive ...

Ozempic and similar weight loss drugs have been found to cut risks for a variety of health issues — ranging from heart to kidney disease — netting the pharma companies behind them billions of ...

When Americans begin taking appetite-suppressing drugs like Ozempic and Wegovy, the changes extend well beyond the bathroom scale. According to new research, the medications are associated with ...

Ozempic to be available in 0.25 mg, 0.5 mg and 1 mg doses in India Lowest dose priced at $24.35 per week India has most type 2 diabetes cases after China Dec 12 (Reuters) - Novo Nordisk (NOVOb.CO), ...

A new study finds a possible association between GLP-1 drugs like semaglutide and chronic cough, though the authors are calling for more research. Reading time 2 minutes Every drug has its risks, no ...

Warning: This graphic requires JavaScript. Please enable JavaScript for the best experience. Industry insiders are gearing up for weight-loss drugs to shake up the ...

“Ozempic is about to be old news,” my colleague Yasmin Tayag wrote in 2023, just before an even more powerful obesity drug, tirzepatide, then best known as Mounjaro, was approved. Well, two years ...